RH
Roche Holding AG
RHHBY · OTC
$54.30 -0.61% (-$0.33)
1M -6.20%
Market Cap CHF 286.7B
P/E Ratio 22.26x
Div. Yield 2.84%
ROE 40.61%
Bulios Fair Price
$35.27
35.0% downside
Current Price
$54.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RHHBY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
52 /100
Fair PEG 0.40x
P/E 22.26x
P/B 8.47x
Growth
25 /100
Declining FCF growth 0.28%
EPS growth 0.17%
Book val. growth 6.53%
Profitability
100 /100
Strong Op. margin 29.16%
Gross margin 73.73%
FCF margin 21.23%
Quality
92 /100
Excellent ROA 12.78%
ROIC 19.71%
Asset turnover 0.63x
Debt
75 /100
Low Int. coverage 14.22x
Debt/Equity 0.94x
Net debt/EBITDA 1.20x
Stability
70 /100
Stable EPS volatility 39.22%
Beta 0.35x
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RHHBY
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Thomas Schinecker
Employees
103,249
Headquarters
Basel
Upcoming events
04 FEB
Earnings
Upcoming earnings report